Association of medication adherence and treatment satisfaction among psychiatric outpatients

2019 ◽  
Vol 60 (4) ◽  
Author(s):  
Viswam Subeesh ◽  
Hemendra Singh ◽  
Jocob Jissna ◽  
Simon Sonia
Keyword(s):  
Medication Adherence ◽  
Treatment Satisfaction ◽  
Psychiatric Outpatients

Impact of constipation on opioid therapy management among long-term opioid users, based on a patient survey

2015 ◽  
Vol 11 (4) ◽  
pp. 325 ◽  
Author(s):  
Shaloo Gupta, MS ◽  
Haridarshan Patel, PharmD ◽  
Justin Scopel, MD, MBA ◽  
Reema R. Mody, MBA, PhD
Keyword(s):  
Quality Of Life ◽  
Medication Adherence ◽  
Treatment Satisfaction ◽  
Linear Models ◽  
Productivity Loss ◽  
Work Productivity ◽  
Opioid Therapy ◽  
Activity Impairment ◽  
Cross Sectional

Objective: The authors sought to characterize health-related quality of life (HRQoL), medication adherence, productivity losses, and treatment satisfaction associated with modifications to opioid therapy due to opioid-induced constipation (OIC).Design: A cross-sectional, between-subjects design was used to examine health outcomes among US noncancer participants currently taking opioids.Patients, participants: Participants were adults in the 2012 US National Health and Wellness Survey, who reported currently using opioids (>30 days) and experiencing constipation. Respondents were categorized as making modifications to opioid therapy due to OIC (modifiers, n = 244) or making no modifications (nonmodifiers, n = 247).Main outcome measures: Patient Assessment of Constipation Quality of Life (PAC-QoL) and Symptoms (PAC-Sym), Morisky Medication Adherence Scale (MMAS-4), Work Productivity and Activity Impairment, and the Treatment Satisfaction Questionnaire for Medication (TSQM II) for OIC treatment were administered. Generalized linear models were adjusted to control for baseline characteristics (age, gender, comorbidities, opioid strength, etc). Results: Modifiers reported poorer HRQoL (PAC-QoL total: 1.74 vs 1.44, p < 0.001), worse constipation (PAC-Sym total: 1.56 vs 1.35, p = 0.003), more pain-related resource use (surgery: odds ratio (OR) = 3.72, p = 0.002; emergency room visits: OR = 1.88, p = 0.049; hospitalizations: OR = 2.47, p = 0.033), and lower adherence (MMAS-4 pain: OR = 0.12, p < 0.001; MMAS-4 OIC: OR = 0.39, p < 0.001) than nonmodifiers. Modifiers reported greater presenteeism (49.75 percent vs 38.28 percent, p = 0.038), but no significant differences were found for activity impairment or OIC treatment satisfaction.Conclusions: Treating OIC effectively may help prevent inadequate pain management secondary to opioid therapy modification, help increase HRQoL, lessen OIC symptoms, decrease productivity loss, and improve adherence to opioid and OIC treatments.

Quality of Life and Its Association With Treatment Satisfaction, Adherence to Medication, and Trust in Physician Among Patients With Hypertension

2018 ◽  
Vol 23 (6) ◽  
pp. 532-542 ◽  
Author(s):  
Siba Jneid ◽  
Hicham Jabbour ◽  
Aline Hajj ◽  
Antoine Sarkis ◽  
Hady Licha ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Medication Adherence ◽  
Psychological Health ◽  
Treatment Satisfaction ◽  
World Health ◽  
Adherence To Treatment ◽  
World Health Organization Quality ◽  
Global Satisfaction ◽  
Adherence To Medication

Objective: Patients with hypertension tend to have a lower health-related quality of life (HRQOL) compared to normotensive patients. This study’s main objectives are to assess (1) HRQOL and factors that might impact it and (2) association between HRQOL and adherence to treatment, trust in physician, and treatment satisfaction among patients with hypertension. Methods: A cross-sectional study enrolled 196 patients from medical-care offices in Beirut, North and South Lebanon. Eligible patients signed a consent form and were asked to complete the Trust in Physician Scale, World Health Organization Quality of Life-brief (WHOQOL-brief) questionnaire, and Treatment Satisfaction Questionnaire (TSQM 1.4) as well as questions assessing medication adherence. Results: Better antihypertensive medication adherence was significantly and positively correlated with better HRQOL domains except general health where significance was not reached ( P = .089). Better adherence was also significantly related to better treatment satisfaction (side effects, convenience, and global satisfaction but not to effectiveness) and an increased trust in physicians ( P < .0001). Better treatment satisfaction (TSQM domains) was significantly and positively associated with a better overall HRQOL ( P ≤ .001). Increased trust in physician scores were significantly and positively correlated with a better psychological health, environment, and overall HRQOL domains ( P = .045, .005, and .006, respectively). Finally, TSQM effectiveness, convenience, and global satisfaction were significantly higher when trust in physician was greater ( P = .017, .035, and .002, respectively). Conclusion: The results of this study revealed an association between increased adherence to treatment, a higher global satisfaction, and an increased quality of life. An increased patient satisfaction with their antihypertensive treatment and trust in their physician were also correlated with a greater adherence to treatment.

Long-term proteasome inhibition in US community multiple myeloma (MM) patients (pts) following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib (I): Updated real-world (RW) data from US MM-6.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19332-e19332
Author(s):  
Saulius Kazmiems Girnius ◽  
Habte Aragaw Yimer ◽  
Sudhir Manda ◽  
Christopher A. Yasenchak ◽  
Veena Charu ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Treatment Satisfaction ◽  
Study Drug ◽  
Progression Free Survival ◽  
Staging System ◽  
Complete Response ◽  
Normal Activity ◽  
Self Report ◽  
Drug Discontinuation ◽  
Activity Levels

e19332 Background: US MM-6 is investigating iCT from parenteral V-based induction to all-oral I-lenalidomide-dexamethasone (IRd) with the aim of increasing proteasome inhibitor (PI)-based treatment adherence/duration while maintaining quality of life (QoL) & further improving outcomes in the diverse US community population. Methods: 21 US community sites, including VA hospitals, are enrolling non-transplant-eligible newly diagnosed MM pts with ≥stable disease after 3 cycles of V-based therapy to receive IRd. Pts use mobile & digital devices to collect actigraphy (activity/sleep) data, complete QoL & treatment satisfaction questionnaires, & self-report medication adherence. Primary endpoint: progression-free survival (PFS); key secondary endpoints include: response rates & duration of therapy. Results: As of Nov 18, 2019, 84 pts had been treated (median age 73 [range 49–90] yrs; 44% ≥75 yrs; 49% male; 15% black/African American; 10% Hispanic/Latino; 35% International Staging System stage III disease; 42% lytic bone disease). Comorbidities included hypertension (57%), anemia (44%), fatigue (43%), & peripheral neuropathy (13%). 85% of pts were receiving VRd at the time of iCT. 62% of pts are still on therapy & enrollment is ongoing. After initiating iCT, ≥complete response (CR) rate increased from 4% to 26% (Table). At 8 mos median follow-up, 6 pts had progressed & there were 2 on-study deaths. The 12-mo PFS rate was 86% (95% CI, 73–93) from the start of V-based regimen & from the start of IRd. During IRd treatment, 92% of pts had treatment-emergent adverse events (TEAEs) (48% grade [G] ≥3). G3 TEAEs (≥5% of pts) were diarrhea (7%), pneumonia (6%), syncope (6%), & anemia (5%). TEAEs led to study drug discontinuation in 7% of pts; 36% had serious TEAEs. I/R/d dose was adjusted due to AEs in 39%/39%/29% of pts. Medication adherence (cycles 1–5) was ‘excellent’/‘very good’ in ≥78% of pts reporting adherence. QoL/treatment satisfaction were maintained in pts completing questionnaires. Actigraphy data showed normal activity levels & sleep durations. Conclusions: US MM-6 pts are representative of the RW US MM population & results show that iCT to an oral PI may permit prolonged PI-based therapy with promising efficacy & without impacting pts’ QoL or treatment satisfaction. Clinical trial information: NCT03173092 . [Table: see text]

Treatment satisfaction and medication adherence among patients with epilepsy at Daoud Charity Clinic, 2021

2021 ◽  
Vol 429 ◽  
pp. 119130
Author(s):  
Abbasher Hussien ◽  
Ahmed Hassan ◽  
Aziza Alrayah ◽  
Sanaa Babiker ◽  
Sara Elhassan ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Treatment Satisfaction ◽  
Patients With Epilepsy

scholarly journals Treatment Satisfaction and Quality of Life among Type 2 Diabetes Patients: A Cross-Sectional Study in West Bank, Palestine

2020 ◽  
Vol 2020 ◽  
pp. 1-8 ◽  
Author(s):  
Maher R. Khdour ◽  
Heba B. Awadallah ◽  
Dua’a H. Al-Hamed
Keyword(s):  
Quality Of Life ◽  
Medication Adherence ◽  
Treatment Satisfaction ◽  
Diabetic Patients ◽  
Health Related Quality ◽  
Cross Sectional ◽  
Quality Of Life Scale ◽  
Related Quality ◽  
Health Related

Objectives. This study had the goal of evaluating the role of treatment satisfaction among diabetic patients in the context of health-related quality of life (QoL) and medication adherence. Methods. This study, which utilized a cross-sectional design, was conducted at the Primary Healthcare Unit in the Ministry of Health in Ramallah between Feb. and May 2019. Medication adherence was evaluated with the 4-item Morisky Green-Levine (MGL) questionnaire, treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM 1.4), and health-related quality of life with the European Quality of Life scale (EQ-5D-3L). Results. Study participants consisted of 380 diabetic patients, of which 220 (57.9%) had high adherence to their medications and 160 (42.1%) had low adherence. Based on the classification of patient responses among the EQ-5D domains, pain/discomfort was the most influenced dimension, with 173 patients (36.1%) reporting problems, (36.1%). Also prominent were anxiety and depression (128 patients, 33.7%) and Mobility (115 patients, 30.3%). A significant relation was observed between QoL and treatment satisfaction (73.8 vs. 69.8; P=0.016). Treatment satisfaction also had a significant association with the anxiety domain (39.4 vs. 28.7; P=0.031). Conclusion. Participants expressed moderate satisfaction with their treatments; more satisfied patients showed greater medication adherence and had better QoL. Anxiety has been shown to be associated with reduced medication adherence and lower QoL.

Sign in / Sign up

Export Citation Format

Share Document